

Effects of *Helicobacter pylori* vacuolating cytotoxin on primary cultures of human gastric epithelial cells

D T Smoot, J H Resau, M H Earlington, M Simpson, T L Cover

Abstract

Background—Many *Helicobacter pylori* strains produce a cytotoxin that induces cytoplasmic vacuolation in various types of eukaryotic cells. In contrast with the marked cell vacuolation that occurs in vitro in response to this cytotoxin, comparatively little epithelial vacuolation has been observed in the gastric mucosa of *H pylori* infected persons.

Aims—Experiments were performed to determine the susceptibility of human gastric epithelial cells in vitro to *H pylori* vacuolating cytotoxin activity.

Methods—Human gastric epithelial cells, harvested from upper gastrointestinal endoscopic biopsy specimens, were incubated overnight with broth culture supernatants from either a wild type cytotoxin producing (tox⁺) *H pylori* strain or an isogenic mutant strain that lacks cytotoxin activity.

Results—Prominent cytoplasmic vacuolation occurred in response to tox⁺ supernatant, but not supernatant from the isogenic mutant strain. Primary human gastric epithelial cells were significantly more sensitive to *H pylori* vacuolating cytotoxin activity than were either HeLa or AGS cells. Exposure of human gastric epithelial cells to high concentrations of tox⁺ supernatant for 48 hours caused lethal cell injury.

Conclusions—These studies indicate that primary human gastric epithelial cells are highly sensitive to *H pylori* vacuolating cytotoxin activity.

(Gut 1996; 39: 795-799)

Keywords: *H pylori*, vacuolating cytotoxin, human gastric cell culture.

Helicobacter pylori is a Gram negative micro-aerophilic bacterium that colonises gastric epithelium and mucus in humans. Infection with this bacterium consistently causes chronic superficial gastritis, which is characterised by infiltration of the mucosa with acute and chronic inflammatory cells.¹ *H pylori* is an important aetiological factor in the development of peptic ulcers, and infection with this organism is a significant risk factor for development of gastric cancer.²⁻⁴ Successful treatment of *H pylori* infection with antibiotics not only heals peptic ulcers, but also greatly reduces ulcer recurrence rates.^{5 6}

One potential virulence factor of *H pylori* is a cytotoxin that induces vacuolation in eukaryotic cells.⁷ Approximately one half of all *H pylori* isolates produce detectable vacuolating cytotoxin activity in vitro. Cytotoxin neutralising antibodies are present in sera from *H pylori* infected persons, which indicates that the cytotoxin is produced in vivo.⁸ In addition, the prevalence of infection with cytotoxin producing *H pylori* strains is higher among infected persons with peptic ulcers than among infected persons with gastritis alone.⁹⁻¹¹ The vacuolating cytotoxin has been purified from *H pylori*, and migrates as a ~90 kDa protein under denaturing and reducing conditions.¹² Insertional mutagenesis of the gene encoding the cytotoxin (vacA) abolishes cytotoxin production.¹³⁻¹⁵ The *H pylori* cytotoxin induces marked vacuolation in vitro in essentially 100% of exposed transformed epithelial cells. Although gastric epithelial cell vacuolation has been reported in *H pylori* infected patients,^{16 17} this morphology has not been a prominent finding in gastric biopsy specimens. One possible explanation for the paucity of epithelial vacuolation in vivo is that gastric epithelial cells may be comparatively resistant to cytotoxin activity. The present studies were designed to determine the sensitivity of cultured primary human gastric epithelial cells to the cytotoxic effects of *H pylori* vacuolating cytotoxin.

Methods

Bacterial strains and growth conditions

H pylori 60190 (ATCC 49503) is a wild type tox⁺ strain, and *H pylori* 60190-v1 is an isogenic mutant strain in which the vacA gene has been disrupted by insertional mutagenesis.¹³ Each strain was cultured in Brucella broth containing 5% fetal bovine serum (BB-FBS) for 48 hours, and after centrifugation of the cultures, supernatants were concentrated 40-fold by ultrafiltration.¹⁸

Culture of primary gastric epithelial cells

Primary human gastric epithelial cells were isolated from gastric biopsy specimens of patients undergoing upper gastrointestinal endoscopy at Howard University Hospital as previously described.¹⁹ Gastric biopsy samples were taken only from patients with macroscopically normal stomach mucosa. Only gastric cells obtained from patients without evidence of *H pylori* on histological evaluation

Gastroenterology
Division,
Department of
Medicine,
Howard University
College of Medicine,
Washington, DC
D T Smoot
M H Earlington
M Simpson

Division of Infectious
Diseases,
Department of
Medicine,
Vanderbilt University
School of Medicine &
Veterans Affairs
Medical Center,
Nashville, TN
T L Cover

ABL-Basic Research
Program,
NCI-Frederick
Cancer Research &
Development Center,
Frederick, MD
H Resau

Correspondence to:
Dr D T Smoot,
Gastroenterology Division,
Howard University Hospital,
2041 Georgia Ave, NW,
Washington, DC 20060,
USA

Accepted for publication
8 July 1996

were used in these experiments. After enzymatic isolation, gastric epithelial cells were plated onto Labtek chamber slides (Nunc Inc, Naperville, IL) and cultured in Ham's F12 culture medium (Life Technologies, Grand Island, NY) at pH 7.4, supplemented with 10% fetal bovine serum (Life Technologies), amphotericin B (0.25 µg/ml), penicillin G (100 units/ml), and streptomycin (100 µg/ml). Cells were cultured for three to five days before each experiment. The effects of *H pylori* supernatant from the wild type tox⁺ strain and the isogenic tox mutant strain on primary cultures on human gastric epithelial cells were compared in four different experiments. Each experiment used gastric cells from a different patient; however, individual experiments were performed using gastric cells from a single patient.

Quantitation of vacuolating cytotoxin activity

Transformed cell lines (HeLa, AGS, HEP2, CHO, MA104, MDCK, and Vero) were cultured in Eagle's medium or Ham's F12 medium (pH=7.4) containing 10% fetal bovine serum, and seeded into 96-well plates. Serial dilutions of *H pylori* culture supernatants or partially purified vacuolating cytotoxin were added to primary cultures of human gastric epithelial cells or transformed cell lines, and incubated for 24 hours at 37°C. Experiments comparing susceptibility of primary gastric cells with transformed cell lines were performed in duplicate and repeated twice. Cell vacuolation was quantitated by visual inspection by two persons blinded to the treatment conditions, using phase contrast microscopy. Alternatively, in some experiments, cell vacuolation was quantitated by neutral red uptake assay.²⁰

Lethal cytotoxicity experiments

Cell viability was assessed by incubating cells in calcein AM and ethidium homodimer (Live/Dead Assay, Molecular Probes, Eugene, OR). Live cells were distinguished by the presence of intracellular esterase activity, which converts the virtually non-fluorescent cell-permeant calcein AM to the intensely fluorescent calcein. The polyanionic calcein is retained within the cytoplasm of live cells, producing an intense uniform green fluorescence. Ethidium homodimer enters cells with damaged membranes and upon binding nucleic acids undergoes a 40-fold enhancement of fluorescence, thereby producing a bright red fluorescence within the nucleus of dead cells. The results are expressed as number of live cells/100 cells counted and represent the data from three separate experiments. Data were analysed for statistical significance using the Student's *t* test.

Results

Effects of the vacuolating cytotoxin on primary gastric epithelial cells

To determine whether human gastric epithelial cells are susceptible to *H pylori* vacuolating

cytotoxin activity, primary cultures of human gastric cells were incubated overnight with concentrated supernatant from tox⁺ *H pylori* strain 60190, its isogenic mutant 60190-v1, or uninoculated concentrated BB-FBS. *H pylori* supernatant from strain 60190 induced prominent vacuoles in the gastric epithelial cells (Fig 1A). In contrast, primary human gastric epithelial cells exposed overnight to culture medium containing either broth supernatant from the mutant *H pylori* strain or uninoculated BB-FBS, did not develop intracellular vacuoles (Fig 1B and C).

Relative susceptibility to vacuolating cytotoxin activity

Early studies by Leunk *et al* suggested that various transformed cell lines differed in susceptibility to cytotoxin activity.⁷ To investigate this phenomenon further, monolayers of seven different cell lines (including four cell lines tested by Leunk *et al*) were incubated with serial dilutions of the vacuolating cytotoxin from *H pylori* 60190, purified partially by hydrophobic interactive chromatography.¹² After 24 hours, cell vacuolation was quantitated by neutral red uptake assay.²⁰ As shown in Figure 2, each of the cell lines tested was susceptible to the effects of *H pylori* cytotoxin, with HeLa, AGS, and Hep-2 cells demonstrated as most sensitive.

We then sought to determine the relative susceptibility of cultured human gastric epithelial cells to cytotoxin activity. Unlike transformed cell lines, normal human gastric epithelial cells in culture do not proliferate at a constant rate and may terminally differentiate over time, which makes standardisation difficult; therefore, for this experiment vacuolation was quantitated by visual inspection rather than using the neutral red assay. As shown in Figure 3, primary human gastric epithelial cells were significantly more susceptible to vacuolating cytotoxin activity than were AGS or HeLa cells.

Lethal vacuolating cytotoxin induced cell injury

Previous studies have suggested that the vacuolating cytotoxin induces reversible, non-lethal injury in transformed cell lines.²¹⁻²³ Therefore, we sought to determine whether the vacuolating cytotoxin induced lethal cell injury in human gastric epithelial cells. Primary cultures of human gastric epithelial cells were incubated for 24 and 48 hours in tissue culture medium containing concentrated broth culture supernatants from *H pylori* strain 60190 or strain 60190-v1, standardised according to protein concentration. Tox⁺ supernatant caused significant lethal gastric epithelial cell injury after 48 hours of incubation (Fig 4). In contrast, supernatant from tox⁻ strain 60190-v1 failed to induce significant lethal cell damage (Fig 4). With incubations longer than 48 hours, the proportion of dead cells increased substantially in control wells, and therefore, these time points could not be evaluated.




Figure 1: Effect of the vacuolating cytotoxin on primary gastric epithelial cells. Primary cultures of human gastric epithelial cells were incubated overnight with, (A) culture medium containing both supernatant from *tox*⁺ *H pylori* strain 60190, (B) culture medium containing both supernatant from the isogenic *H pylori vacA*-mutant strain (60190-v1), or (C) cell culture medium alone. *H pylori* supernatant concentrations were adjusted and standardised to yield a final protein concentration of 2 mg/ml in tissue culture medium. Prominent vacuoles were detected only in cells incubated with supernatant from the *tox*⁺ strain (see arrows in Fig 1A).




Figure 2: Vacuolation of multiple cell lines in response to *H pylori* cytotoxin. Seven different cell lines (10^4 cells/well) were incubated overnight with serial dilutions of partially purified cytotoxin from *tox*⁺ *H pylori* strain 60190 in culture media containing 10 mM ammonium chloride. Vacuolation then was quantitated by neutral red uptake assay.²⁰ HeLa cells were most sensitive to cytotoxin activity, followed by AGS and Hep-2 cells, which had almost identical responses.

Discussion

The results of this study show that human gastric epithelial cells are highly sensitive to the activity of the *H pylori* vacuolating cytotoxin. In several previous studies, vacuolation of gastric epithelial cells has been demonstrated in gastric biopsy specimens from *H pylori* infected persons.^{16 17} However, epithelial cell vacuolation is not a prominent histological feature. Moreover, in one study that compared the gastric histology of patients infected with *tox*⁺ strains with that of patients infected with *tox*⁻ strains, no significant differences in levels of epithelial cell vacuolation were detectable.¹⁸

The activity of the *H pylori* vacuolating cytotoxin on the gastric mucosa has also been assessed by administering purified cytotoxin directly into the stomachs of mice. This procedure results in localised regions of epithelial cell necrosis, loss of cytoplasm, and gastric ulceration in some cases.^{24 25} Administration of bacterial sonicate from *tox*⁺ strain 60190 induces similar epithelial lesions, whereas




Figure 3: Relative susceptibility of primary human gastric epithelial cells to *H pylori* cytotoxin activity. Primary cultures of human gastric epithelial (HGE) cells, AGS cells, and HeLa cells were exposed overnight to serial dilutions of supernatant from *tox⁺* *H pylori* strain 60190. The proportion of cells containing visible vacuoles then was determined by visual inspection, using phase contrast microscopy. Data are expressed as the mean (SD) of triplicate experiments. Primary human gastric epithelial cells were significantly ($p < 0.05$) more susceptible to cytotoxin activity than were HeLa or AGS cells. Statistical analysis performed using Student's *t* test for matched pairs.




Figure 4: Effect of the *H pylori* cytotoxin on cell viability. Primary human gastric epithelial cells were incubated with supernatants from either *tox⁺* *H pylori* strain 60190 or an isogenic *tox⁻* mutant strain (60190-v1), diluted in culture medium to final protein concentrations of 1, 2 or 4 mg/ml. After 24 and 48 hours of incubation, cell viability was assessed by staining with calcein AM and ethidium homodimer. *Tox⁺* supernatant induced significant lethal cell injury after 48 hours of incubation. Statistical analysis was performed using the Student's *t* test. * $p < 0.05$.

sonicate from the isogenic *vacA*-mutant strain 60190-v1 does not.²⁶ Thus, in the mouse model, epithelial cell injury occurs in response to the cytotoxin. In several previous studies, it has been noted that cell vacuolation induced by the cytotoxin in vitro is reversible, either by removal of the cytotoxin or by addition of agents such as bafilomycin A1.²¹⁻²³ The present study shows that exposure of cultured gastric epithelial cells to the cytotoxin for 48 hours results in lethal cell damage. Thus we hypothesise that longterm exposure of gastric epithelial cells to the cytotoxin in vivo may similarly result in cell death.

Several factors probably account for the apparent differences in response to the *H pylori* vacuolating cytotoxin in vitro compared with in vivo. Firstly, in vitro experiments typically involve a single acute exposure of cells to a high concentration of cytotoxin, whereas cells are presumably exposed continuously in vivo to low concentrations of cytotoxin for long periods. Secondly, the mechanism of cytotoxin delivery to cells may be different in vitro and in vivo. For example, direct delivery of cytotoxin to cells from adherent bacteria may result in effects that differ from those produced by bathing cells in high concentrations of soluble cytotoxin.^{27, 28} Thirdly, the response of cells to the cytotoxin may be modified by the presence of various *H pylori* products or host factors (including anti-cytotoxin antibodies) that are present in different concentrations in vivo or in vitro. Finally, cytoplasmic vacuolation may occur more readily or may be more easily detectable in the flattened, adherent cells of a monolayer than in epithelial cells contained within an intact mucosal surface.

Analysis of the in vitro interactions between the *H pylori* cytotoxin and normal human gastric epithelial cells provides insight into the activity of the cytotoxin in vivo, and is potentially a more relevant model than studies using transformed cell lines. At present, the membrane components to which the cytotoxin binds have not been characterised. However, the relatively greater susceptibility of primary cells to the cytotoxin compared with several types of transformed cells suggests that an increased number of cytotoxin receptors may be present on the surface of primary cells. In future studies, it will be useful to test this hypothesis by quantitating cytotoxin binding to primary cells versus various transformed cell lines.

The authors would like to thank Drs Sadye Curry, Hemant Joglekar, Joseph Nidiry, and Victor Scott for their assistance in collecting gastric biopsy samples.

This work was supported in part by Public Health Service Grant GM08244, an HBCU grant from the Medical Research Service of the Department of Veterans Affairs, and Glaxo, Inc; and in part by the National Cancer Institute, DHHS, under contract with ABL.

- Cover TL, Blaser MJ. *Helicobacter pylori* infection, a paradigm for chronic mucosal inflammation: pathogenesis and implications for eradication and prevention. *Adv Intern Med* 1996; 41: 85-117.
- Correa P, Fox J, Fontham E, Ruiz B, Lin Y, Zavala D, et al. *Helicobacter pylori* and gastric carcinoma. *Cancer* 1990; 66: 2569-74.
- Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. *Helicobacter pylori* infection and the risk of gastric carcinoma. *N Engl J Med* 1991; 325: 1127-31.
- Hansson LE, Engstrand L, Nyren O, Evans DJ, Lingren A, Bergstrom R, et al. *Helicobacter pylori* infection: independent risk indicator of gastric adenocarcinoma. *Gastroenterology* 1993; 105: 1098-103.
- Forbes GM, Glaser ME, Cullen DJE, Warren JR, Christiansen KJ, Marshall BJ, et al. Duodenal ulcer treated with *Helicobacter pylori* eradication: seven-year follow-up. *Lancet* 1994; 343: 258-60.
- Labenz J, Borsch G. Highly significant change of the clinical course of relapsing and complicated peptic ulcer disease after cure of *Helicobacter pylori* infection. *Am J Gastroenterol* 1994; 89: 1785-8.
- Leunk RD, Johnson PT, David BC, Draft WG, Morgan DR. Cytotoxic activity in broth-culture filtrates of *Campylobacter pylori*. *J Med Microbiol* 1988; 26: 98-9.
- Cover TL, Cao P, Murthy UK, Sipple MS, Blaser MJ. Serum neutralizing antibody response to the vacuolating cytotoxin of *Helicobacter pylori*. *J Clin Invest* 1992; 90: 913-8.

- 9 Tee W, Lambert JR, Dwyer B. Cytotoxin production by *Helicobacter pylori* from patients with upper gastrointestinal tract diseases. *J Clin Microbiol* 1995; **33**: 1203-5.
- 10 Figura N, Guglielmetti P, Rossolinia A, Barberi A, Cusi G, Musmanno RA, *et al.* Cytotoxin production by *Campylobacter pylori* strains isolated from patients with peptic ulcers and from patients with chronic gastritis only. *J Clin Microbiol* 1989; **27**: 225-6.
- 11 Atherton JC, Cao P, Peek RM Jr., Tummuru MKR, Blaser MJ, Cover TL. Mosaicism in vacuolating cytotoxin alleles of *Helicobacter pylori*: association of specific vacA types with cytotoxin production and peptic ulceration. *J Biol Chem* 1995; **270**: 17771-7.
- 12 Cover TL, Blaser MJ. Purification and characterization of the vacuolating toxin from *Helicobacter pylori*. *J Biol Chem* 1992; **267**: 10570-5.
- 13 Cover TL, Tummuru MKR, Cao P, Thompson SA, Blaser MJ. Divergence of genetic sequences for the vacuolating cytotoxin among *Helicobacter pylori* strains. *J Biol Chem* 1994; **269**: 10566-73.
- 14 Schmitt W, Hass R. Genetic analysis of the *Helicobacter pylori* vacuolating cytotoxin: structural similarities with the IgA protease type of exported protein. *Mol Microbiol* 1994; **12**: 307-19.
- 15 Phadnis SH, Ilver D, Janzon L, Normark S, Westblom TU. Pathological significance and molecular characterization of the vacuolating toxin gene of *Helicobacter pylori*. *Infect Immun* 1994; **62**: 1557-65.
- 16 Tricottet V, Bruneval P, Vire O, Camilleri PJ. *Campylobacter*-like organisms and surface epithelium abnormalities in active, chronic gastritis in humans: an ultrastructural study. *Ultrastruct Pathol* 1986; **10**: 113-22.
- 17 Hessey SJ, Spencer J, Wyatt JL, Sabala G, Rathbone BJ, Axon ATR, *et al.* Bacterial adhesion and disease activity in *Helicobacter* associated chronic gastritis. *Gut* 1990; **31**: 134-8.
- 18 Cover TL, Cao P, Lind CD, Tham KT, Blaser MJ. Correlation between vacuolating cytotoxin production by *Helicobacter pylori* isolates in vitro and in vivo. *Infect Immun* 1993; **61**: 5008-12.
- 19 Smoot DT, Resau JH, Naab T, Desbordes BC, Gilliam T, Bull-Henry K, *et al.* Adherence of *Helicobacter pylori* to cultured human gastric epithelial cells. *Infect Immun* 1993; **61**: 350-5.
- 20 Cover TL, Puryear W, Perez-Perez GI, Blaser MJ. Effect of urease on HeLa cell vacuolation induced by *Helicobacter pylori* cytotoxin. *Infect Immun* 1991; **59**: 1264-70.
- 21 Cover TL, Reddy LY, Blaser MJ. Effects of ATPase inhibitors on the response of HeLa cells to *Helicobacter pylori* vacuolating toxin. *Infect Immun* 1993; **61**: 1427-31.
- 22 Papini E, Bugnoli M, DeBernard M, Figura N, Rappuoli R, Montecucco C. Bafilomycin A1 inhibits *Helicobacter pylori*-induced vacuolization of HeLa cells. *Mol Microbiol* 1993; **7**: 323.
- 23 Cover TL, Halter SA, Blaser MJ. Characterization of HeLa cell vacuoles induced by *Helicobacter pylori* broth culture supernatant. *Hum Pathol* 1992; **23**: 1004-10.
- 24 Telford JL, Ghiara P, Dell'Orco M, Comanducci M, Burrioni D, Bugnoli M, *et al.* Gene structure of the *Helicobacter pylori* cytotoxin and evidence of its key role in gastric disease. *J Exp Med* 1994; **179**: 1653-8.
- 25 Marchetti M, Arico B, Burrioni D, Figura N, Rappuoli R, Ghiara P. Development of a mouse model of *Helicobacter pylori* infection that mimics human disease. *Science* 1995; **267**: 1655-8.
- 26 Ghiara P, Marchetti M, Blaser MJ, Tummuru MKR, Cover TL, Segal ED, *et al.* Role of the *Helicobacter pylori* virulence factors vacuolating cytotoxin, CagA and urease in a mouse model of disease. *Infect Immun* 1995; **63**: 4154-60.
- 27 Zafri D, Oron Y, Eisenstein BI, Ofek I. Growth advantage and enhanced toxicity of *Escherichia coli* adherent to tissue culture cells due to restricted diffusion of products secreted by the cells. *J Clin Invest* 1987; **79**: 1210-6.
- 28 Ofek I, Zafri D, Goldhar J, Eisenstein BI. Inability of toxin inhibitors to neutralize enhanced toxicity caused by bacteria adherent to tissue culture cells. *Infect Immun* 1990; **58**: 3737-42.